Previous 10 | Next 10 |
home / stock / biovf / biovf news
Swedish Orphan Biovitrum AB (BIOVF) Q2 2022 Earnings Conference Call July 19, 2022 07:00 AM ET Company Participants Guido Oelkers - CEO Henrik Stenqvist - CFO Anders Ullman - Head, R&D and CMO Armin Reininger - Head of Medical and Scientific Affairs ...
Swedish Orphan Biovitrum AB press release ( OTCPK:BIOVF ): Q2 Non-GAAP EPS of -SEK0.91. Revenue of SEK3.87M (+20.6% Y/Y) misses by SEK352.44M . EBITA SEK 944 M (922); EBITA margin 24 per cent (29). Items affecting comparability ( IAC ) of SEK -14 M i...
The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2022 Q2 earnings call. For further details see: Swedish Orphan Biovitrum AB (publ) 2022 Q2 - Results - Earnings Call Presentation
Amid the biotech bear market, there are companies that are trading on a deep bargain, yet you should be extremely careful before averaging down. Though I noticed the fundamental changes in Galapagos, I gave the company a year to turn around. Here, I presented to you three differen...
Swedish Orphan Biovitrum AB (BIOVF) Q1 2022 Earnings Conference Call April 28, 2022 07:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financial Officer Anders Ullman - Head of Research & Development, Chief Medical Officer Armin Reininger - H...
The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2022 Q1 earnings call. For further details see: Swedish Orphan Biovitrum AB (publ) 2022 Q1 - Results - Earnings Call Presentation
Swedish Orphan Biovitrum AB press release (OTCPK:BIOVF): Q1 Non-GAAP EPS of SEK 3.67. Revenue of SEK 4.92B (+34.1% Y/Y). For further details see: Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 3.67, revenue of SEK 4.92B
The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2021 Q4 earnings call. For further details see: Swedish Orphan Biovitrum AB (publ) 2021 Q4 - Results - Earnings Call Presentation
Swedish Orphan Biovitrum AB press release (OTCPK:BIOVF): Q4 Non-GAAP EPS of SEK4.21. Revenue of SEK4.9B (+7.0% Y/Y). 2022 outlook: Revenue is anticipated to grow by a mid to high single-digit percentage at CER vs. estimated growth of 6.48% Y/Y; EBITA margin is anticipated to be at a low ...
Swedish Orphan Biovitrum AB (publ) Q2 2022 Earnings Conference Call July 21, 2021 07:00 ET Company Participants Guido Oelkers - Chief Executive Officer Ravi Rao - Head, Research & Development Henrik Stenqvist - Chief Financial Officer Conference Call Participants Eun Yang - Jefferies Chri...
News, Short Squeeze, Breakout and More Instantly...
Swedish Orphan Biovit Ord Company Name:
BIOVF Stock Symbol:
OTCMKTS Market:
WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi ® ), today announced the presentation of three abstracts that highlights data from its myelofibrosis treatment option at the American Society of Clin...
WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi ® ), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to emapalumab-lzsg being investigated as a pot...
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...